{"id":236590,"date":"2025-04-07T15:19:12","date_gmt":"2025-04-07T15:19:12","guid":{"rendered":"https:\/\/peoplebugs.com\/health\/as-rfk-jr-champions-chronic-disease-prevention-key-research-is-cut\/"},"modified":"2025-04-07T16:22:21","modified_gmt":"2025-04-07T16:22:21","slug":"as-rfk-jr-champions-chronic-disease-prevention-key-research-is-cut","status":"publish","type":"post","link":"https:\/\/peoplebugs.com\/health\/as-rfk-jr-champions-chronic-disease-prevention-key-research-is-cut\/","title":{"rendered":"As RFK Jr. Champions Chronic Disease Prevention, Key Research Is Cut"},"content":{"rendered":"
\n<\/p>\n
Robert F. Kennedy Jr. has spoken of an \u201cexistential threat\u201d that he said can destroy the nation.<\/p>\n
\u201cWe have the highest chronic disease burden of any country in the world,\u201d Mr. Kennedy said at a hearing in January before the Senate confirmed him as the secretary of Health and Human Services.<\/p>\n
And on Monday he is starting a tour in the Southwest<\/a> to promote a program to combat chronic illness, emphasizing nutrition and lifestyle.<\/p>\n But since Mr. Kennedy assumed his post, key grants and contracts that directly address these diseases, including obesity, diabetes and dementia, which experts agree are among the nation\u2019s leading health problems, are being eliminated.<\/p>\n These programs range in scale and expense. Researchers warn that their demise could mean lost opportunities to address an aspect of public health that Mr. Kennedy has said is his priority.<\/p>\n<\/div>\n<\/div>\n \u201cThis is a huge mistake,\u201d said Dr. Ezekiel Emanuel, the co-director of the Healthcare Transformation Institute at the University of Pennsylvania\u2019s Perelman School of Medicine.<\/p>\n Ever since its start in 1996, the Diabetes Prevention Program has helped doctors understand this deadly chronic disease. The condition is the nation\u2019s most expensive, affecting 38 million<\/a> Americans and incurring $306 billion<\/a> in one recent year in direct costs. With about 400,000 deaths<\/a> in 2021, it was the eighth leading cause of death.<\/p>\n The program has been terminated, and the reason has little to do with its merits. Instead, it seems to be a matter of a lead researcher\u2019s working in the wrong place at the wrong time.<\/p>\n The program began when doctors at 27 medical centers received funding from the National Institutes of Health for a study asking whether Type 2 diabetes could be prevented. The 3,234 participants had high risk of the disease.<\/p>\n<\/div>\n<\/div>\n The results were a huge victory. Those assigned to follow a healthy diet and exercise routine regularly reduced their chances of developing diabetes by 58 percent. Those who took metformin, a drug that lowers blood sugar, decreased their risk by 31 percent.<\/p>\n<\/div>\n<\/div>\n The program entered a new phase, led by Dr. David M. Nathan, a diabetes expert at Harvard Medical School. Researchers followed the participants to see how they fared without the constant attention and support of a clinical trial. The researchers also examined their genetics and metabolism and looked at measures of frailty and cognitive function.<\/p>\n Several years ago, the investigators had an idea. Some studies suggested that people with diabetes had a higher risk of dementia. But scientists didn\u2019t know if it was vascular dementia or Alzheimer\u2019s or what the precise risk factors were. The diabetes program could renew its focus on investigating this with its 1,700 aging participants.<\/p>\n The group added a new principal investigator, the dementia expert Dr. Jose A. Luchsinger. For administrative reasons, including the newfound focus on dementia, the program decided its money should flow through Dr. Luchsinger\u2019s home institution, Columbia University, rather than through Harvard or George Washington University, where a third principal investigator works.<\/p>\n On March 7, the Trump administration cut $400 million in grants and contracts to Columbia<\/a>, saying Jewish students were not protected from harassment during protests over the war in Gaza. The diabetes grant was among those terminated<\/a>: $16 million a year that Columbia shared across 30 medical centers. The study ended abruptly.<\/p>\n<\/div>\n<\/div>\n Asked about the termination, Andrew G. Nixon, director of communications at Health and Human Services, provided a statement from the agency\u2019s acting general counsel saying that \u201canti-Semitism is clearly inconsistent with the fundamental values that should inform liberal education\u201d and that \u201cColumbia University\u2019s complacency is unacceptable.\u201d<\/p>\n At the time their grant ended, the researchers had started advanced cognitive testing for evidence of dementia in patients, followed by brain imaging to look for amyloid, the hallmark of Alzheimer\u2019s disease. They planned to complete the tests during the next two years.<\/p>\n Then, Dr. Luchsinger said, the group was going to look at blood biomarkers of amyloid and other signs of dementia, including brain inflammation. For comparison, they planned to perform the same tests on participants\u2019 blood samples from 7 and 15 years ago.<\/p>\n \u201cVery few studies have blood collected and stored going that far back,\u201d Dr. Luchsinger said.<\/p>\n Now much of the work cannot begin, and the part that had started remains incomplete.<\/p>\n Another troubling question the researchers hoped to answer was whether metformin increases, decreases or has no effect on the risk of dementia.<\/p>\n<\/div>\n<\/div>\n \u201cThis is the largest and longest study of metformin ever,\u201d Dr. Luchsinger said. Participants assigned to take the drug in the 1990s took it for more than 20 years.<\/p>\n \u201cWe thought we had the potential to put to rest this question about metformin,\u201d Dr. Luchsinger said.<\/p>\n The only ways to save the program, Dr. Nathan said, are for Mr. Kennedy to agree to restore the funding at Columbia or to transfer the grant to a principal investigator at another medical center.<\/p>\n<\/div>\n<\/div>\n The study investigators are appealing to the diabetes caucus in Congress, hoping it can help make their case to the Health and Human Services.<\/p>\n<\/div>\n<\/div>\nDecades of Diabetes Research Discontinued<\/span><\/h3>\n